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Because of the recent expiry of a large number of patents on the originator biological products, interest in
the production and marketing of similar biotherapeutic products in Brazil has been increasing. The
national producers have signiﬁcant interest in this market and have been making a large amount of
investments in these kinds of products.
Since biotherapeutic products consume a large amount of the government health budget, the Brazilian
government also has a big interest in the possibility that more affordable biotherapeutic products could
be introduced into the market to improve access, but always is concerned with the quality, safety and
efﬁcacy of these products Accordingly, it was necessary to review the biological product regulations in
Brazil and to establish speciﬁc pathways to license similar biotherapeutic products.
The new Brazilian regulations, Resolution n 55/2010, are based on different regulations and guidelines
from around the world, including the WHO SBP Guidelines. They follow the same scientiﬁc principles as
the WHO Guidelines but also have some differences which are due to speciﬁc country needs.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
Nowadays, most of the biological products licensed in Brazil are
produced abroad, normally in Europe or USA. In Brazil, there are only
some national producers that produce vaccines and during the last
year, these producers started the production of biotherapeutic prod-
ucts such as erythropoietin and interferon through technology
transfer. Thesenationalproducersbelong to theBraziliangovernment.
Due to the increase in the number of expiring patents on bio-
logical products during the last three years, the interest and
investment of private and public national producers in the bio-
logical market has increased. A large number of national producers
have started projects to develop and produce biological products in
Brazil. The aim is to produce new products as well as re-creating
biological products that are not innovations.
In Brazil, the use of different biological products (vaccines,
biotherapeutic products, monoclonal antibodies, blood derivative
products) for different types of treatment is covered by the
government through speciﬁc Health Programs of the Ministry of
Health and it consumes a signiﬁcant portion of the health budget.
For example, the biotherapeutic products represent 2% of all
medicines distributed by the government through speciﬁc(L. G. Castanheira), Dirceu.
ech@anvisa.gov.br (N. Rech).
ll rights reserved. The World Healthprograms, but represent 41% of total amount that the Ministry of
Health spends on medicines in speciﬁc health programs annually.
Similarly, amongst the biological products themselves, monoclonal
antibodies represent 1% of the total amount of biotherapeutic
products distributed but account for 32% of total amount spent on
biological products by Brazilian Ministry of Health [1,2].
Thus, the Brazilian Government has a big interest in these kinds
of products especially if they could be produced in large numbers
by national and international producers so as to increase their
availability, reduce costs and improve access. But it is clear that
potential opportunities to reduce prices and increase access need to
occur with the assurance that the products themselves will be of
high quality, safety and efﬁcacy.
Updating the biological regulations to deal with this new
scenariowill have a key role in developing the biological industry in
Brazil.2. Legislative basis and approach
Up to 2002, there was no speciﬁc regulation for biological
products in Brazil. In 2002 the ﬁrst regulation related to biological
products in Brazil (RDC 80/2002) was published [3]. This regulation
had the same pathway for new biological products and copies. The
applicant needed to present a full dossier with whole quality
information and a complete clinical development (non-clinical
data, Phase I, II and III studies data).Organization has granted the Publisher permission for the reproduction of this article.
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[4], with a new regulation regarding biological products. This regu-
lation still had the same pathway for both new biological products
andcopiesand theapplicantwasstill required topresent a full dossier
with the whole quality information and to complete the clinical
development (non-clinical data, Phase I, II and III studies data).
In view of the considerable interest and questions both
nationally and internationally regarding the regulatory oversight of
similar biotherapeutic products, it was necessary to update the
Brazilian Regulations related to biological products. Thus, at the
beginning of 2010, ANVISA published a draft of a new set of regu-
lations called, a Public Consultation 49/2010 (CP 49/10) [5] and by
the end of 2010, the new regulation (RDC 55/2010) [6] was pub-
lished. This new regulation has different and speciﬁc regulatory
pathways for new biological products and for copies.
This regulation has been proposed for biological products in
Brazil and has the classical pathway for new biotherapeutic prod-
ucts, based on a full dossier presentation by the applicant.
For the similar biotherapeutic products, there are two regula-
tory pathways: a comparative pathway and an individual devel-
opment pathway.
According to the new regulation in Brazil, the new bio-
therapeutic products are called new biological products and the
copies are called biological products that can be licensed by the
comparative pathway or the individual development pathway. The
information about the pathway used to license the copies are
available in the approval letter, inserts and package of the product.
In the individual development pathway, a reduced dossier can
be presented. The applicant needs to present complete data
regarding quality issues but it does not have to be comparative.
Non-clinical and clinical studies can be reduced, depending on the
amount of knowledge of pharmacological properties, safety and
efﬁcacy of the originator product. At least one comparative Phase III
study (equivalence or non-inferiority) with the originator (new)
biological product is mandatory. Extrapolation of indications will
not be accepted in the individual development pathway.
Two similar biological products have been licensed using the
comparability pathway, a GCS-F (ﬁlgrastim) and a growth hormone,
and some products like monoclonal antibodies and enzymes in
development under ANVISA monitoring.
Regarding the individual development pathway, there is one
biological product, a low molecular weight heparin, licensed using
this approach and two other products under development under
ANVISA monitoring.
3. Experience of individual pathway application for the
development of a biotherapeutic product in Brazil
Hepatitis C infection is the most common cause of chronic viral
hepatitis in the developed world. It is estimated that there are 200
million chronic hepatitis patients worldwide, and that the infection
progresses to cirrhosis, in at least, 25% patients and 2e5% of this
25% progresses to hepatocelullar carcinoma every year.
In Brazil, the use of IFN and Peg-IFN for hepatitis treatment is
covered by the government through a speciﬁc health program of
the Ministry of Health named Exceptional High Cost Medicines
Programs and it consumes a signiﬁcant portion of health budget.
Thus, the Brazilian Government has a big interest in biotherapeutic
products that could be produced by a public national producer with
high quality, safety and efﬁcacy but at a lower cost.
In Brazil, we have the experience in the application of the
individual development pathway, which is on course with a pegy-
lated interferon.
During 2004, a public producer laboratory in Brazil, signed
a technology transfer contract with a Cuban producer fortechnology transfer of IFN-alpha 2b production from Cuba to Brazil.
Since 2005, the Brazilian and Cuban NRAs, ANVISA and CECMED,
respectively, have been following the project of technology transfer.
In 2005, following the signing of the technology transfer agreement
between Biomanguinhos and CIGB, the Brazilian and Cuban NRAs
established a Technical Regulatory Committee (TRC) to follow all
the activities related to the technology transfer projects.
The aim of TRC is to follow all the steps related to the technology
transfer activities from the very early stages, giving the necessary
regulatory instructions and the technical support for project
development, so as to assure that products of high quality, safety
and efﬁcacy will be made available to the public.
The TRC has members from different areas of the Brazilian and
Cuban NRAs (licensing, GMP and GCP inspections, clinical trials,
Pharmacovigilance) as well as members from different areas of the
Cuban and Brazilian producers (R & D, production, quality control,
quality assurance, Pharmacovigilance).
The interferon alpha 2b project has been followed by the TRC
from the start and is still being monitored. The TRC has also been
following the development of a pegylated interferon alpha 2b from
Cuban and Brazilian producers.
The regulatory pathway for this product is the individual devel-
opment pathway, which is midway between that of a new product
development and of a biosimilar, because they developed a new
pegylation technology and a new pegylatedmolecule that is similar,
but not identical, to a pegylated interferon alpha 2b already licensed
in Brazil. This new pegylated molecule will be conjugated to the
already licensed Interferon alpha 2b from the Brazilian producer
that has the quality, efﬁcacy and safety proﬁle well established.
All the development steps for this new product are being eval-
uated and discussed with the NRAs through TRC and the NRAs are
monitoring the implementation of each activity related to the
product development by the producers, through joint work in GMP
and GCP inspections, protocols and dossiers reviews, etc.
As already mentioned, the comparator biological product (CBP)
chosen for the non-clinical and clinical phases is a pegylated
interferon already licensed in Brazil.
The batches for non-clinical and clinical studies are ready and
the production was followed by the TRC. All the development and
quality aspects established were non-comparative.
The non-clinical studies have already ﬁnished, and non-
comparative and comparative studies have been conducted. The
producers conducted two non-comparative studies with rodents
(Spragu Dawley rats), local tolerance and acute toxicity studies. A
PK comparative study was conducted with New Zealand Rabbits,
but the comparator in this study was the native non pegylated
interferon alpha 2b from Cuban and Brazilian producers. A
comparative study using CBP was conducted in monkeys (Macaca
fascicularius), which was a long term toxicity study.
The non-clinical data showed that the repeated administration
of product is well tolerated and it is not toxic in doses 130X higher
than therapeutic doses. PK studies demonstrated a signiﬁcant
increase in bioavailability of Pegylated interferon alpha 2b
compared to non pegylated interferon. The comparative study with
CBP showed a satisfactory degree of comparability in terms of
toxicokinetics, PD and immunogenicity.
Now the producers are starting the Phase I investigation,
a comparative study (with CBP), double blind, crossover study with
healthy volunteers and with a 4 week wash out period. The aim of
this study is to compare PK, PD and safety parameters of CBP and
the new product. The study protocol was previously discussed and
approved by TRC and has been monitored by joint GCP inspections
by ANVISA and CECMED.
As soon as the Phase I study is ﬁnished, a Phase II/III study will
start. A previous discussion regarding this study was conducted by
Table 1
Comparsion between critical aspects of Brazilian new regulation and WHO SBP guideline.
Element Brazil (comparative pathway) WHO Comparsion
Reference to Regulations Speciﬁc (Brazil) General statements referring reader
to local situation
Different
Development pathway
for similar biotherapeutic
products (SBP)
Comparative and individual development pathway Comparative pathway Signiﬁcant
differences
Choice of reference
biological product
Related to product assessed and licensed by ANVISA
and marketed in Brazil and abroad based in a full data package
General deﬁnition that the reference
biological need have to been marketed
for a suitable duration
Similar
Quality and Comparability No reference to international guidelines like EMA and ICH Reference to EMA Guidelines and
ICH documents
Different
Non-clinical and clinical studies Less detailed, because all the details about design and
statistical analysis will be addressed in a speciﬁc technical
guideline, which is sometimes product speciﬁc. Regarding this,
issues will be published with the new regulation. More
emphasis on Clinical Studies but non-clinical studies
are not dispensable
Details have a general balance suited
to a general guideline: increased
emphasis on design and
statistical considerations.
Few differences
Pharmaceutical and/or
therapeutic equivalence
Authorization of SEB is not a declaration of pharmaceutical
and/or therapeutic equivalence
Authorization of SEB is not a
declaration of pharmaceutical
and/or therapeutic equivalence
Similar
Extrapolation to
other indications
Extrapolation is possible according to regulation but is
addressed in a general way. This issue will be addressed
in product speciﬁc guidelines according Brazilian
Regulatory Authority Experience
More speciﬁc guidance Few Differences
Pharmacovigillance Speciﬁc pharamcovigillance plan and post market reports Speciﬁc pharamcovigillance plan
and post market reports
Similar
Patent questions; no-ﬁling
period of time of SEB
Brazilian regulation regarding license of SEB is not related
to patent issues. There is no speciﬁc period of time after
the originator biological authorization that the SEB
applicant is prohibited to present the SEB dossier in ANVISA.
Not addressed Similar
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onewith the investigation product and the other two arms with the
two pegylated interferons already licensed in Brazil), double blind
randomized study, with HCV patients with a minimum period
duration of 48 weeks. The primary endpoints will be virus remis-
sion (quantitative PCR) at week 24 and secondary endpoints will be
virological response at weeks 4, 12, and 48; changes in liver
biochemistry (including transaminases) and level of morbidity. The
antibody production and safety issues will be evaluated as well.
After this study, the need and extension of the immunogenicity
study will by discussed by the TRC.
The approved indication for the pegylated interferon produced
by Brazil and Cuba will be through treatment of Hepatitis caused
by HCV.
According to the ﬁndings in Phase II/III study, a Pharmacovigi-
lance Plan and Risk management Plan will be established by the
producers and discussed with TRC andmust be presented as part of
marketing authorization dossier.
In this case, the individual development pathway has been
developed because the quality aspects were established in a non-
comparative with CBP basis. The non-clinical studies were major
non-comparative and we had one comparative study. All the clin-
ical development (Phase I and Phase II/III studies) will be
comparative.4. Brazilian regulation compared to WHO guideline
Brazilian regulation is based on different regulations around the
world. The Biological coordination in ANVISA, which is the Brazilian
regulatory authority, studied and used as basis regulations or
proposal of regulations from different regions and countries such as
Canada, Cuba, Europe, Japan, Korea, etc. In addition, the WHO
guideline was used as a basis as well. Added to that, this subject has
been discussed by ANVISA at the regional level (Latin America,Central America, Caribbean): Mercosur, PARF, Oaxaca Group, etc
and at the international level.
There are no signiﬁcant differences between the comparative
pathway in the new Brazilian Regulations and the WHO guideline.
The major differences are related to speciﬁc issues in Brazilian laws
and the national context.
Is important to note that in Brazil, only the copies licensed by
comparability pathway are considered as biosimilars and could
claim for extrapolation of indications.
The other pathway for the copies, the individual development
pathway, is suitable for some speciﬁc biotherapeutics, and will
depend on many conditions and restrictions, such as the need for
non-clinical studies, complete clinical development with Phase I, II
and III studies as well as a Phase III comparative study with CPB,
where the extrapolation of indications is not possible.
The Table 1 shows the comparison of main elements related to
WHO guideline and Brazil regulation.
5. Conclusion
The proposed new regulations in RDC 55/2010 are expected to
ﬁll a large number of gaps that were present in the existing Bra-
zilian regulations, and will give technical and scientiﬁc directions
that will be suitable for the new market context of Brazilian bio-
therapeutic products.
In contrast to previous regulations, this new regulation estab-
lishes speciﬁc pathways for copies of biological products.
During the development of the new regulations, experiences,
examples and regulations of different countries with very different
situations were considered and adapted as necessary to the Bra-
zilian situation and context.
The new Brazilian regulation has a lot of similarities with the
WHO SBP Guideline. There are general common concepts, such as
the need for a speciﬁc pathway for similar biotherapeutic products,
the use of a reference biological product based on a suitable period
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mation on quality, efﬁcacy and safety, as well as the need for
a speciﬁc Pharmacovigillance.
The major differences are due the speciﬁc country context. For
example, in Brazil we have the same regulation for biotherapeutic
products, vaccines, blood derivative products, hyperimmune sera,
probiotics, etc, where a comparative approach would not be suit-
able.Whilewe have proposed the individual development pathway
this should not be the ﬁrst pathway of choice for a biotherapeutic
product. The selection of the individual development pathway for
a biotechnology product will depend on many conditions and
restrictions, such as the need for non-clinical studies, complete
clinical development with Phase I, II and III studies and a Phase III
comparative study, and prohibition of extrapolation of indications.
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